Robert H Shaw
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
Shaw, Robert H; Greenland, Melanie; Stuart, Arabella S V; Aley, Parvinder K; Andrews, Nick J; Cameron, J. Claire; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Darton, Tom; Dinesh, Tanya; Duncan, Christopher J A; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; Goodman, Anna L; Green, Christopher A; Hallis, Bassam; Heath, Paul T; Hill, Helen; Lambe, Teresa; Libri, Vincenzo; Lillie, Patrick J; Morey, Ella; Mujadidi, Yama F; Payne, Ruth; Plested, Emma L; Provstgaard-Morys, Samuel; Ramasamy, Maheshi N; Mary Ramsay, Ffph; Read, Robert C; Hannah Robinson, R N; Screaton, Gavin R; Singh, Nisha; Turner, David P.J.; Turner, Paul J; White, Rachel; Nguyen-Van-Tam, Jonathan S.; Liu, Xinxue; Snape, Matthew D
Authors
Melanie Greenland
Arabella S V Stuart
Parvinder K Aley
Nick J Andrews
J. Claire Cameron
Sue Charlton
Elizabeth A Clutterbuck
Andrea M Collins
Tom Darton
Tanya Dinesh
Christopher J A Duncan
Saul N Faust
Daniela M Ferreira
Adam Finn
Anna L Goodman
Christopher A Green
Bassam Hallis
Paul T Heath
Helen Hill
Teresa Lambe
Vincenzo Libri
Patrick J Lillie
Ella Morey
Yama F Mujadidi
Ruth Payne
Emma L Plested
Samuel Provstgaard-Morys
Maheshi N Ramasamy
Ffph Mary Ramsay
Robert C Read
R N Hannah Robinson
Gavin R Screaton
Nisha Singh
DAVID TURNER david.turner@nottingham.ac.uk
Clinical Associate Professor
Paul J Turner
Rachel White
JONATHAN NGUYEN-VAN-TAM Jonathan.Nguyen-Van-tam1@nottingham.ac.uk
Senior Strategy Adviser
Xinxue Liu
Matthew D Snape
Abstract
Background: Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms used in homologous and heterologous priming combinations, which will inform the choice of vaccine platform in future vaccine development. Methods: Com-COV2 was a single-blinded trial in which adults ≥ 50 years, previously immunised with single dose ‘ChAd’ (ChAdOx1 nCoV-19, AZD1222, Vaxzevria, Astrazeneca) or ‘BNT’ (BNT162b2, tozinameran, Comirnaty, Pfizer/BioNTech), were randomised 1:1:1 to receive a second dose 8–12 weeks later with either the homologous vaccine, or ‘Mod’ (mRNA-1273, Spikevax, Moderna) or ‘NVX’ (NVX-CoV2373, Nuvaxovid, Novavax). Immunological follow-up and the secondary objective of safety monitoring were performed over nine months. Analyses of antibody and cellular assays were performed on an intention-to-treat population without evidence of COVID-19 infection at baseline or for the trial duration. Findings: In April/May 2021, 1072 participants were enrolled at a median of 9.4 weeks after receipt of a single dose of ChAd (N = 540, 45% female) or BNT (N = 532, 39% female) as part of the national vaccination programme. In ChAd-primed participants, ChAd/Mod had the highest anti-spike IgG from day 28 through to 6 months, although the heterologous vs homologous geometric mean ratio (GMR) dropped from 9.7 (95% CI (confidence interval): 8.2, 11.5) at D28 to 6.2 (95% CI: 5.0, 7.7) at D196. The heterologous/homologous GMR for ChAd/NVX similarly dropped from 3.0 (95% CI:2.5,3.5) to 2.4 (95% CI:1.9, 3.0). In BNT-primed participants, decay was similar between heterologous and homologous schedules with BNT/Mod inducing the highest anti-spike IgG for the duration of follow-up. The adjusted GMR (aGMR) for BNT/Mod compared with BNT/BNT increased from 1.36 (95% CI: 1.17, 1.58) at D28 to 1.52 (95% CI: 1.21, 1.90) at D196, whilst for BNT/NVX this aGMR was 0.55 (95% CI: 0.47, 0.64) at day 28 and 0.62 (95% CI: 0.49, 0.78) at day 196. Heterologous ChAd-primed schedules produced and maintained the largest T-cell responses until D196. Immunisation with BNT/NVX generated a qualitatively different antibody response to BNT/BNT, with the total IgG significantly lower than BNT/BNT during all follow-up time points, but similar levels of neutralising antibodies. Interpretation: Heterologous ChAd-primed schedules remain more immunogenic over time in comparison to ChAd/ChAd. BNT-primed schedules with a second dose of either mRNA vaccine also remain more immunogenic over time in comparison to BNT/NVX. The emerging data on mixed schedules using the novel vaccine platforms deployed in the COVID-19 pandemic, suggest that heterologous priming schedules might be considered as a viable option sooner in future pandemics. ISRCTN:27841311 EudraCT:2021-001275-16.
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 31, 2023 |
Online Publication Date | Apr 6, 2023 |
Publication Date | 2023-06 |
Deposit Date | Apr 19, 2023 |
Publicly Available Date | Apr 19, 2023 |
Journal | Journal of infection |
Print ISSN | 0163-4453 |
Electronic ISSN | 1532-2742 |
Peer Reviewed | Peer Reviewed |
Volume | 86 |
Issue | 6 |
Pages | 574-583 |
DOI | https://doi.org/10.1016/j.jinf.2023.03.027 |
Keywords | Protein, Antibody, Vaccine, Adenovirus vector, Vaccination, Persistence, T cell, Adjuvant, Cellular, Humoral, Subgroup, Heterologous, T-cell, immunology, homologous, Tcell, Sars-cov2, Covid, Mrna Lipid Nanoparticle |
Public URL | https://nottingham-repository.worktribe.com/output/19779082 |
Publisher URL | https://www.journalofinfection.com/article/S0163-4453(23)00199-8/fulltext |
Related Public URLs | https://www.sciencedirect.com/science/article/pii/S0163445323001998 |
PMID | 37028454 |
Files
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
(4.2 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
(2021)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search